Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user switched from topical to oral finasteride and minoxidil for hair loss and experienced swelling and sensitivity in the left chest area. They are concerned about these symptoms but noticed improvement after skipping a dose.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The user is experiencing hair loss and has been using treatments like minoxidil, finasteride, and ciclopirox olamine. Despite these treatments, they are concerned about increased shedding, dandruff, and possible additional hair loss conditions.

A user experienced a hard lump under their nipple and increased hair loss after four months of finasteride. They are concerned about the lump and plan to stop the treatment.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

After jaw surgery caused intense hair shedding and scalp itch, using pyrilutamide significantly reduced these symptoms. It's suggested to test pyrilutamide for authenticity before use, despite positive personal experience with the product from MV Supplements.

The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.

The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.

The conversation discusses using latanoprost for hair loss treatment. Participants also mention Minoxidil, finasteride, and RU58841 as other treatments.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation is about sourcing Latanoprost for hair loss treatment. Users discuss potential sources and the difficulty of obtaining a prescription.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The user is considering using dutasteride or finasteride for hair loss and has recurrent folliculitis. Another user suggests treating the folliculitis and notes diffuse thinning.

An 18-year-old experienced chest pain, headaches, and vomiting after taking oral minoxidil for hair loss. They reduced the dosage, felt better, but experienced sharp chest pain again after increasing it, and are advised to stop the medication and see a doctor.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.